Research ExplorerPublicationsIntermediate-dose methotrexate in the treatment of childhood...

Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.

Standard

Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy. / Janka-Schaub, Gritta; Winkler, K; Jürgens, H; Goebel, U; Gutjahr, P; Spaar, H J.

In: EUR J PEDIATR, Vol. 145, No. 1-2, 1-2, 1986, p. 14-17.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Janka-Schaub, G, Winkler, K, Jürgens, H, Goebel, U, Gutjahr, P & Spaar, HJ 1986, 'Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.', EUR J PEDIATR, vol. 145, no. 1-2, 1-2, pp. 14-17. <http://www.ncbi.nlm.nih.gov/pubmed/3525176?dopt=Citation>

APA

Janka-Schaub, G., Winkler, K., Jürgens, H., Goebel, U., Gutjahr, P., & Spaar, H. J. (1986). Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy. EUR J PEDIATR, 145(1-2), 14-17. [1-2]. http://www.ncbi.nlm.nih.gov/pubmed/3525176?dopt=Citation

Vancouver

Janka-Schaub G, Winkler K, Jürgens H, Goebel U, Gutjahr P, Spaar HJ. Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy. EUR J PEDIATR. 1986;145(1-2):14-17. 1-2.

Bibtex

@article{db92b26fa4d740928ac4644d6726ac4b,
title = "Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.",
abstract = "One hundred and fifty-one children with acute lymphocytic leukaemia (ALL) received multiple agent induction chemotherapy followed by intensive phase treatment. One hundred and thirty-seven patients were randomised for the first year of maintenance treatment to receive reinforcement therapy (pulses) with either intermediate-dose methotrexate (ID-MTX) and prednisone (PRED) or vincristine (VCR) and PRED. The probability of continuous complete remission (CCR) at 5.5 years is 0.80 for the ID-MTX group and 0.84 for the VCR group. Extramedullary relapses were not prevented either in the ID-MTX group nor in the VCR group. Since in previous studies VCR/PRED pulses did not increase CCR rates when given after intensive combination chemotherapy, it can be concluded from this study that neither did ID-MTX reinforcement therapy further improve treatment results in our patients with ALL when given after aggressive chemotherapy.",
author = "Gritta Janka-Schaub and K Winkler and H J{\"u}rgens and U Goebel and P Gutjahr and Spaar, {H J}",
year = "1986",
language = "Deutsch",
volume = "145",
pages = "14--17",
journal = "EUR J PEDIATR",
issn = "0340-6199",
publisher = "Springer",
number = "1-2",

}

RIS

TY - JOUR

T1 - Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.

AU - Janka-Schaub, Gritta

AU - Winkler, K

AU - Jürgens, H

AU - Goebel, U

AU - Gutjahr, P

AU - Spaar, H J

PY - 1986

Y1 - 1986

N2 - One hundred and fifty-one children with acute lymphocytic leukaemia (ALL) received multiple agent induction chemotherapy followed by intensive phase treatment. One hundred and thirty-seven patients were randomised for the first year of maintenance treatment to receive reinforcement therapy (pulses) with either intermediate-dose methotrexate (ID-MTX) and prednisone (PRED) or vincristine (VCR) and PRED. The probability of continuous complete remission (CCR) at 5.5 years is 0.80 for the ID-MTX group and 0.84 for the VCR group. Extramedullary relapses were not prevented either in the ID-MTX group nor in the VCR group. Since in previous studies VCR/PRED pulses did not increase CCR rates when given after intensive combination chemotherapy, it can be concluded from this study that neither did ID-MTX reinforcement therapy further improve treatment results in our patients with ALL when given after aggressive chemotherapy.

AB - One hundred and fifty-one children with acute lymphocytic leukaemia (ALL) received multiple agent induction chemotherapy followed by intensive phase treatment. One hundred and thirty-seven patients were randomised for the first year of maintenance treatment to receive reinforcement therapy (pulses) with either intermediate-dose methotrexate (ID-MTX) and prednisone (PRED) or vincristine (VCR) and PRED. The probability of continuous complete remission (CCR) at 5.5 years is 0.80 for the ID-MTX group and 0.84 for the VCR group. Extramedullary relapses were not prevented either in the ID-MTX group nor in the VCR group. Since in previous studies VCR/PRED pulses did not increase CCR rates when given after intensive combination chemotherapy, it can be concluded from this study that neither did ID-MTX reinforcement therapy further improve treatment results in our patients with ALL when given after aggressive chemotherapy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 145

SP - 14

EP - 17

JO - EUR J PEDIATR

JF - EUR J PEDIATR

SN - 0340-6199

IS - 1-2

M1 - 1-2

ER -